While canonical plasma markers such as phosphorylated tau and beta-amyloid fragments, including our plasma Aβ1−40, aim to detect direct products from the brain, the biomarkers in our panel, such as LGALS3BP, ACE, and POSTN, may reflect secondary effects in the periphery that are primarily caused by AD brain pathology. This evidence concerns the gene LGALS3BP and Alzheimer disease.